IP Library Granted Patent US 9,133,503
Granted Patent B2
US 9,133,503 · App. 13/479,634 · Granted Sep 15, 2015

Kits for detection of nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,133,503
App. No.
13/479,634
Granted
Sep 15, 2015
Kind
B2
Abstract

The present invention relates to compositions and methods for the detection and characterization of small nucleic acid molecules (e.g., RNA (e.g., small RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs)) and other short nucleic acid molecules). More particularly, the present invention relates to methods for the detection and quantification of RNA expression. The present invention further provides for the detection of miRNA and siRNA variants.

Claims (21)

1. A kit for detecting an miRNA target comprising a first region, a second region, and a third region, wherein said first region is downstream of and contiguous to said second region, and wherein said second region is downstream of and contiguous to said third region, comprising:

i) a first oligonucleotide having a 3′ end, wherein said first oligonucleotide comprises a 3′ portion that is complementary to said first region of said miRNA target, and a 5′ portion that is not complementary to said miRNA target, wherein said 3′ portion of said first oligonucleotide comprises the 3′ end of said first oligonucleotide;

ii) a second oligonucleotide having a 3′ end, wherein said second oligonucleotide comprises a 3′ portion that is substantially homologous to said third region of said miRNA target and a 5′ portion that is not homologous to said third region of said miRNA target, wherein said 3′ portion of said second oligonucleotide comprises the 3′ end of said second oligonucleotide;

iii) a reverse transcriptase;

iv) a DNA polymerase;

v) a 5′ nuclease;

vi) a probe oligonucleotide, wherein at least a portion of said probe oligonucleotide is complementary to at least a portion of said second region of said miRNA target; and

vii) a first stacker oligonucleotide comprising a 5′ terminal portion, wherein at least the 5′ terminal portion of said stacker oligonucleotide is complementary to a region in said 5′ portion of said first oligonucleotide adjacent to said 3′ portion of said first oligonucleotide.

2. The kit of claim 1 , wherein said 5′ nuclease is thermostable.

3. The kit of claim 1 , wherein said probe oligonucleotide is unlabeled and contains a 5′ and 3′ region, wherein said 3′ region is complementary to said second region of said miRNA target; and wherein said 5′ region is non-complementary to said miRNA target and forms a 5′ flap.

4. The kit of claim 1 , wherein said 3′ portion of said first oligonucleotide is configured to form a duplex of about 6-10 base pairs with said miRNA.

5. The kit of claim 1 , further comprising a second stacker oligonucleotide comprising a 5′ terminal portion, wherein at least the 5′ terminal portion of said second stacker oligonucleotide is complementary to a region of said 5′ portion said second oligonucleotide adjacent to said 3′ portion of said second oligonucleotide.

6. The kit of claim 1 , wherein said probe is a labeled probe configured for FRET detection.

7. The kit of claim 1 , wherein said miRNA is selected from the group consisting of Let-7, miR-1, miR-135, miR-15, miR-16, miR125b, miR-1d, and miR124a.

8. The kit of claim 1 , wherein said 5′ nuclease comprises a modified DNA polymerase, wherein said modified DNA polymerase has 5′ nuclease activity but lacks synthetic activity.

9. The kit of claim 3 , further comprising an oligonucleotide cassette, wherein a portion of said oligonucleotide cassette is complementary to said 5′ region of said probe oligonucleotide, wherein said oligonucleotide cassette is configured to form an invasive cleavage structure with said non-target cleavage product from said cleavage of said probe oligonucleotide.

10. The kit of claim 9 , wherein said oligonucleotide cassette is configured for FRET detection.

11. The kit of claim 1 , wherein said 5′ nuclease is a FEN-1 endonuclease.

12. The kit of claim 11 , wherein said FEN-1 endonuclease comprises a thermostable FEN-1.

13. The kit of claim 12 , wherein said FEN-1 endonuclease is from an archaebacterial species.

14. The kit of claim 13 , wherein said archaebacterial species is selected from the group consisting of: Pyrococcus furiosus, Methanococcus jannaschii, Archaeoglobus veneficus and Archaeoglobus fulgidus.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2012
From: LYAMICHEV, VICTOR; ALLAWI, HATIM T.
To: THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 028585/0446 →